RBC Capital Markets Raises Price Target on Acadia Pharmaceuticals
RBC Capital Markets increased its price target for Acadia Pharmaceuticals to $41 from $31 while maintaining an Outperform rating.
Stocks · News reference
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Acadia Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting total revenues of $342 million.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Raises Price Target on ACADIA Pharmaceuticals to $38 From $36
RBC Capital Markets increased its price target for Acadia Pharmaceuticals to $38 from $36 while maintaining an 'Outperform' rating, citing continued momentum for the drug Daybue.
ACADIA Pharmaceuticals Q3 EPS $0.31 Beats $0.20 Estimate, Sales $342.291M Beat $332.468M Estimate
8-K filing — ACADIA PHARMACEUTICALS INC (ACAD)
Filed: 2026-11-04 AccNo: 0001193125-26-447276 Size: 525 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
AcadeMedia Releases Interim Report for Q1 2026/27
AcadeMedia AB (publ) has published its interim report for the first quarter of the 2026/27 fiscal year.
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Acadia Pharmaceuticals announced its participation in a fireside chat at the upcoming UBS Global Biopharma Conference 2026.